皮下脂膜炎样T细胞淋巴瘤研究进展

doi:10.35541/cjd.20230172

中华皮肤科杂志 ›› 2024, e0230172.doi: 10.35541/cjd.20230172

皮下脂膜炎样T细胞淋巴瘤研究进展

徐教生¹ 伏利兵² 徐哲¹ 徐子刚¹

¹国家儿童医学中心首都医科大学附属北京儿童医院皮肤科，北京 100045；²国家儿童医学中心首都医科大学附属北京儿童医院病理科，北京 100045

收稿日期:2023-03-28 修回日期:2024-03-11 发布日期:2024-11-12
通讯作者: 徐子刚 E-mail:zigangxu@yahoo.com

Subcutaneous panniculitis?like T cell lymphoma

Xu Jiaosheng¹, Fu Libing², Xu Zhe¹, and Xu Zigang¹

¹Department of Dermatology, Beijing Children′s Hospital, Capital Medical University, National Center for Children′s Health, Beijing 100045, China; ²Department of Pathology, Beijing Children′s Hospital, Capital Medical University, National Center for Children′s Health, Beijing 100045, China

Received:2023-03-28 Revised:2024-03-11 Published:2024-11-12
Contact: Xu Zigang E-mail:zigangxu@yahoo.com

摘要/Abstract

摘要： 【摘要】皮下脂膜炎样T细胞淋巴瘤存在甲型肝炎病毒细胞受体2基因的高频突变，这一发现为该病的发病机制研究开辟了新思路，同时也为该病的诊断、治疗及预后判断提供依据。本文对皮下脂膜炎样T细胞淋巴瘤的新近研究成果进行综述。

关键词: 白血病淋巴瘤, 成人T细胞, 突变, 诊断, 鉴别, 药物疗法, 预后, 皮下脂膜炎样T细胞淋巴瘤, 脂膜炎, 红斑狼疮性, 淋巴组织细胞增多症, 嗜血细胞性, 甲型肝炎病毒细胞受体2基因

Abstract: 【Abstract】 High-frequency mutations in the hepatitis A virus cellular receptor 2 gene have been detected in subcutaneous panniculitis-like T-cell lymphoma, which paves a new way for studying the pathogenesis of this disorder, and provides a basis for its diagnosis, treatment, and prognosis assessment. This review summarizes the latest research achievements in subcutaneous panniculitis-like T-cell lymphoma.

Key words: Leukemia-lymphoma, adult T-cell, Mutation, Diagnosis, differential, Drug therapy, Prognosis, Subcutaneous panniculitis-like T-cell lymphoma, Panniculitis, lupus erythematosus, Lymphohistiocytosis, hemophagocytic, Hepatitis A virus cellular receptor 2 gene

徐教生伏利兵徐哲徐子刚. 皮下脂膜炎样T细胞淋巴瘤研究进展[J]. 中华皮肤科杂志, 2024,e0230172. doi:10.35541/cjd.20230172

Xu Jiaosheng, Fu Libing, Xu Zhe, and Xu Zigang. Subcutaneous panniculitis?like T cell lymphoma[J]. Chinese Journal of Dermatology,2024,e0230172. doi:10.35541/cjd.20230172

参考文献 43

［1］	Gonzalez CL, Medeiros LJ, Braziel RM, et al. T⁃cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome［J］. Am J Surg Pathol, 1991,15（1）:17⁃27. doi: 10.1097/00000478⁃1991 01000⁃00002.
［2］	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms［J］. Blood, 2016,127（20）:2375⁃2390. doi: 10.1182/blood⁃2016⁃01⁃643569.
［3］	Gau JP, Yang CF, Liu JH, et al. Subcutaneous panniculitis⁃like T cell lymphoma: familial aggregation while different response to chemotherapy［J］. Int J Hematol, 2009,89（1）:63⁃65. doi: 10. 1007/s12185⁃008⁃0202⁃4.
［4］	Nguyen MC, Nguyen V, Le H, et al. Subcutaneous panniculitis⁃like T⁃cell lymphomas with homozygous inheritance of HAVCR2 mutations in Vietnamese pedigrees［J］. Pediatr Blood Cancer, 2021,68（12）:e29292. doi: 10.1002/pbc.29292.
［5］	Gayden T, Sepulveda FE, Khuong⁃Quang DA, et al. Germline HAVCR2 mutations altering TIM⁃3 characterize subcutaneous panniculitis⁃like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome［J］. Nat Genet, 2018,50（12）:1650⁃1657. doi: 10.1038/s41588⁃018⁃0251⁃4.
［6］	Polprasert C, Takeuchi Y, Kakiuchi N, et al. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. Blood Adv, 2019,3（4）:588⁃595. doi: 10.1182/bloodadvances.2018028340.
［7］	Sonigo G, Battistella M, Beylot⁃Barry M, et al. HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. Blood, 2020,135（13）:1058⁃1061. doi: 10.1182/blood.2019003811.
［8］	Koh J, Jang I, Mun S, et al. Genetic profiles of subcutaneous panniculitis⁃like T⁃cell lymphoma and clinicopathological impact of HAVCR2 mutations［J］. Blood Adv, 2021,5（20）:3919⁃3930. doi: 10.1182/bloodadvances.2021004562.
［9］	Guitart J, Mangold AR, Martinez⁃Escala ME, et al. Clinical and pathological characteristics and outcomes among patients with subcutaneous panniculitis⁃like T⁃cell lymphoma and related adipotropic lymphoproliferative disorders［J］. JAMA Dermatol, 2022,158（10）:1167⁃1174. doi: 10.1001/jamadermatol.2022.3347.
［10］	Moonla C, Polprasert C, Komvilaisak P, et al. Germline HAVCR2 mutations and their relation to the clinical spectrum of subcutaneous panniculitis⁃like T⁃cell lymphoma and hemophagocytic lymphohistiocytosis: results from a multicenter study and meta⁃analysis［J］. Haematologica, 2023,108（10）:2743⁃2752. doi: 10.3324/haematol.2022.282419.
［11］	LeBlanc RE, Lansigan F. Unraveling subcutaneous panniculitis⁃like T⁃cell lymphoma: an association between subcutaneous panniculitis⁃like T⁃cell lymphoma, autoimmune lymphoproliferative syndrome, and familial hemophagocytic lymphohistiocytosis［J］. J Cutan Pathol, 2021,48（4）:572⁃577. doi: 10.1111/cup.13863.
［12］	徐基昕, 李彦格, 刘炜, 等. 家族性噬血细胞综合征继发皮下脂膜炎样T细胞淋巴瘤一例并文献复习［J］. 白血病·淋巴瘤, 2021,30（11）:670⁃673. doi: 10.3760/cma.j.cn115356⁃20210409⁃00075.
［13］	Li Z, Lu L, Zhou Z, et al. Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. Br J Haematol, 2018,181（3）:406⁃410. doi: 10.1111/bjh.14611.
［14］	Bashey S, Krathen M, Abdulla F, et al. Romidepsin is effective in subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. J Clin Oncol, 2012,30（24）:e221⁃e225. doi: 10.1200/JCO.2012.41.5976.
［15］	Nemoto Y, Taniguchi A, Kamioka M, et al. Epstein⁃Barr virus⁃infected subcutaneous panniculitis⁃like T⁃cell lymphoma associated with methotrexate treatment［J］. Int J Hematol, 2010,92（2）:364⁃368. doi: 10.1007/s12185⁃010⁃0642⁃5.
［16］	Matsuoka A, Fujii K, Higashi Y, et al. Subcutaneous panniculitis⁃like T⁃cell lymphoma associated with methotrexate treatment［J］. J Dermatol, 2022,49（12）:e430⁃e432. doi: 10.1111/1346⁃8138. 16524.
［17］	Eser B, Altuntas F, Er O, et al. A case of subcutaneous panniculitis⁃like T⁃cell lymphoma with haemophagocytosis developing secondary to chemotherapy［J］. J Eur Acad Dermatol Venereol, 2004,18（6）:713⁃715. doi: 10.1111/j.1468⁃3083.2004. 01043.x.
［18］	Nakamura H, Sugai T, Kato M, et al. Subcutaneous panniculitis⁃like T⁃cell lymphoma with haemophagocytic syndrome during tocilizumab therapy for juvenile idiopathic arthritis［J］. Clin Exp Rheumatol, 2017,35（1）:174.
［19］	Sluzevich JC, Hall MR, Roy V. Subcutaneous panniculitis⁃like T⁃cell lymphoma after rituximab［J］. J Am Acad Dermatol, 2012,67（5）:e223⁃e225. doi: 10.1016/j.jaad.2012.04.023.
［20］	Hahtola S, Burghart E, Jeskanen L, et al. Clinicopathological characterization and genomic aberrations in subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. J Invest Dermatol, 2008,128（9）:2304⁃2309. doi: 10.1038/jid.2008.6.
［21］	Mangan MS, Sarici AM, Yalcin O, et al. Orbital mass as the only presenting sign with overlapping features of lupus erythematosus panniculitis and subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. Ocul Immunol Inflamm, 2023,31（4）:717⁃720. doi: 10.1080/09273948.2022.2054430.
［22］	Bosisio F, Boi S, Caputo V, et al. Lobular panniculitic infiltrates with overlapping histopathologic features of lupus panniculitis （lupus profundus） and subcutaneous T⁃cell lymphoma: a conceptual and practical dilemma［J］. Am J Surg Pathol, 2015,39（2）:206⁃211. doi: 10.1097/PAS.0000000000000307.
［23］	Wu X, Subtil A, Craiglow B, et al. The coexistence of lupus erythematosus panniculitis and subcutaneous panniculitis⁃like T⁃cell lymphoma in the same patient［J］. JAAD Case Rep, 2018,4（2）:179⁃184. doi: 10.1016/j.jdcr.2017.08.021.
［24］	Tawanwongsri W, Thongsroy J. Subcutaneous panniculitis⁃like T⁃cell lymphoma with a transformation to lupus erythematosus panniculitis: a case report［J］. Case Rep Dermatol, 2022,14（3）:319⁃325. doi: 10.1159/000527530.
［25］	Machan S, Rodríguez M, Alonso⁃Alonso R, et al. Subcutaneous panniculitis⁃like T⁃cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes［J］. Leuk Lymphoma, 2021,62（9）:2130⁃2140. doi: 10.1080/10428194.2021.1901098.
［26］	de Mingo Pulido Á, Hänggi K, Celias DP, et al. The inhibitory receptor TIM⁃3 limits activation of the cGAS⁃STING pathway in intra⁃tumoral dendritic cells by suppressing extracellular DNA uptake［J］. Immunity, 2021,54（6）:1154⁃1167. doi: 10.1016/j.immuni.2021.04.019.
［27］	Zhang Y, Wang Z, Hu G, et al. A novel germline HAVCR2 （TIM⁃3） compound heterozygous mutation is related to hemophagocytic lymphohistiocytic syndrome in EBV⁃positive peripheral T⁃cell lymphoma （NOS） with down⁃regulated TIM⁃3 signaling［J］. Front Oncol, 2022,12:870676. doi: 10.3389/fonc.2022.870676.
［28］	Maliniemi P, Hahtola S, Ovaska K, et al. Molecular characterization of subcutaneous panniculitis⁃like T⁃cell lymphoma reveals upregulation of immunosuppression⁃ and autoimmunity⁃associated genes［J］. Orphanet J Rare Dis, 2014,9:160. doi: 10.1186/s13023⁃014⁃0160⁃2.
［29］	Honda Y, Otsuka A, Nonomura Y, et al. CCR5 and CXCR3 expression in a case of subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. J Eur Acad Dermatol Venereol, 2016,30（8）:1413⁃1415. doi: 10.1111/jdv.13258.
［30］	Li Z, Wang H, Dong R, et al. Single⁃cell RNA⁃seq reveals characteristics of malignant cells and immune microenvironment in subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. Front Oncol, 2021,11:611580. doi: 10.3389/fonc.2021.611580.
［31］	Liau JY, Chuang SS, Chu CY, et al. The presence of clusters of plasmacytoid dendritic cells is a helpful feature for differentiating lupus panniculitis from subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. Histopathology, 2013,62（7）:1057⁃1066. doi: 10.1111/his.12105.
［32］	López⁃Lerma I, Peñate Y, Gallardo F, et al. Subcutaneous panniculitis⁃like T⁃cell lymphoma: clinical features, therapeutic approach, and outcome in a case series of 16 patients［J］. J Am Acad Dermatol, 2018,79（5）:892⁃898. doi: 10.1016/j.jaad.2018. 05.1243.
［33］	Duan Y, Gao H, Zhou C, et al. A retrospective study of 18 children with subcutaneous panniculitis⁃like T⁃cell lymphoma: multidrug combination chemotherapy or immunomodulatory therapy?［J］. Orphanet J Rare Dis, 2022,17（1）:432. doi: 10. 1186/s13023⁃022⁃02575⁃4.
［34］	Michonneau D, Petrella T, Ortonne N, et al. Subcutaneous panniculitis⁃like T⁃cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy［J］. Acta Derm Venereol, 2017,97（3）:358⁃364. doi: 10.2340/00015555⁃2543.
［35］	Lee WS, Hwang JH, Kim MJ, et al. Cyclosporine A as a primary treatment for panniculitis⁃like T cell lymphoma: a case with a long⁃term remission［J］. Cancer Res Treat, 2014,46（3）:312⁃316. doi: 10.4143/crt.2014.46.3.312.
［36］	Heyman B, Beaven A. Mycophenolate mofetil for the treatment of subcutaneous panniculitis⁃like T⁃cell lymphoma: case report and review of the literature［J］. Clin Lymphoma Myeloma Leuk, 2018,18（10）:e437⁃e440. doi: 10.1016/j.clml.2018.07.283.
［37］	Dietrich C, Keller A, Enk A, et al. Subcutaneous panniculitis⁃like T⁃cell lymphoma: brief review and report of successful treatment with mycophenolate mofetil［J］. Clin Exp Dermatol, 2022,47（7）:1360⁃1363. doi: 10.1111/ced.15145.
［38］	Mehta N, Wayne AS, Kim YH, et al. Bexarotene is active against subcutaneous panniculitis⁃like T⁃cell lymphoma in adult and pediatric populations［J］. Clin Lymphoma Myeloma Leuk, 2012,12（1）:20⁃25. doi: 10.1016/j.clml.2011.06.016.
［39］	Watson LR, Lew TE, Fox LC, et al. Ruxolitinib bridging therapy to allogeneic SCT for high⁃risk refractory subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. Leuk Lymphoma, 2022,63（13）:3217⁃3221. doi: 10.1080/10428194.2022.2118537.
［40］	Hansen S, Alduaij W, Biggs CM, et al. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: a case series［J］. Eur J Haematol, 2021,106（5）:654⁃661. doi: 10. 1111/ejh.13593.
［41］	曲双, 廖丽昇, 谢颖, 等. PD⁃1单抗联合化疗治疗皮下脂膜炎样T细胞淋巴瘤一例报告并文献复习［J］. 中华血液学杂志, 2021,42（11）:959⁃961. doi: 10.3760/cma.j.issn.0253⁃2727. 2021.11.013.
［42］	Jothishankar B, Espinosa ML, Zain J, et al. Complete response to romidepsin as monotherapy in treatment⁃resistant subcutaneous panniculitis⁃like T⁃cell lymphoma［J］. JAAD Case Rep, 2020,6（12）:1245⁃1247. doi: 10.1016/j.jdcr.2020.09.018.
［43］	Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis⁃like T⁃cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases［J］. Blood, 2008,111（2）:838⁃845. doi: 10. 1182/blood⁃2007⁃04⁃087288.

[1]	中国儿童鲜红斑痣诊断和治疗专家共识制订专家组中国医师协会皮肤科医师分会儿童学组. [开放获取] 儿童鲜红斑痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 396-404.
[2]	中国医师协会皮肤科医师分会中华医学会皮肤病学分会治疗学组中国医疗保健国际交流促进会皮肤医学分会国家皮肤与免疫疾病临床医学研究中心中国罕见病联盟皮肤罕见病专业委员会. 大疱性类天疱疮诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 405-415.
[3]	中国中西医结合学会皮肤性病专业委员会皮肤肿瘤学组中国抗癌协会黑色素瘤专业委员会中国抗癌协会皮肤肿瘤整合康复专业委员会. [开放获取] 色素痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 387-395.
[4]	万勇军杨海晶严翘陈梅王逢源粟倩雅董正邦王飞. 免疫检查点抑制剂相关Stevens-Johnson综合征/中毒性表皮坏死松解症9例临床及预后分析[J]. 中华皮肤科杂志, 2025, 58(4): 347-351.
[5]	中国医师协会皮肤科医师分会儿童学组中华医学会皮肤性病学分会银屑病学组. 【开放获取】儿童脓疱型银屑病诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 297-306.
[6]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤罕见病专业委员会国家皮肤与免疫疾病临床医学研究中心. 【开放获取】副肿瘤性天疱疮诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 289-296.
[7]	王雪颖王真真王喆糜自豪孙乐乐刘红张福仁. 中国汉族家族性良性慢性天疱疮患者的功能丧失突变与较早的发病年龄相关[J]. 中华皮肤科杂志, 2025, 58(3): 221-227.
[8]	陈瑶余浪姜倩喻惠元陈柳青陈金波. 大疱性类天疱疮和天疱疮光学相干断层扫描成像特征比较[J]. 中华皮肤科杂志, 2025, 58(3): 216-220.
[9]	陈启韬李煜乾邵光辉朱晶朱麒麟李中明杜旭峰范卫新. 头皮糜烂性脓疱性皮病研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 272-275.
[10]	秦蓓李钦峰. 蓝莓松饼婴儿病因学研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20220411-e20220411.
[11]	袁勇勇潘萌. 家族性慢性良性天疱疮研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240182-e20240182.
[12]	董艺穆妮热·塔伊尔闫昕章星琪. 机器学习在皮肤疾病中的研究应用[J]. 中华皮肤科杂志, 2025, 0(3): 20240290-e20240290.
[13]	高西波魏然秦蓓廉佳李钦峰. Ⅰ型神经纤维瘤病新发NF1基因移码突变1例[J]. 中华皮肤科杂志, 2025, 58(2): 174-175.
[14]	中国中西医结合学会皮肤性病专业委员会中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 常见非黑素细胞性皮肤肿瘤的反射式共聚焦显微镜特征专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 20-33.
[15]	中国康复医学会皮肤病康复专业委员会中国中西医结合学会皮肤性病专业委员会老年皮肤病学组. [开放获取] 老年皮肤瘙痒症诊疗与康复专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 1-8.

皮下脂膜炎样T细胞淋巴瘤研究进展

Subcutaneous panniculitis?like T cell lymphoma

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 15

Metrics

本文评价

推荐阅读 10